The improved disease-free survival rates in EBC with the integration of adjuvant CDK4/6 inhibitor therapy into clinical practice contribute to a rising workload for medical oncologists who are also facing a rising prevalence of cancer cases globally. This evidence concerns the gene CDK4 and cancer.